{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-22-002335","form_type":"8-K","ticker":"PMCB","cik":"0001157075","company_name":"PharmaCyte Biotech, Inc.","filed_at":"2022-04-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:59.886182+00:00","generated_at":"2026-06-26T09:19:19.249090+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"PharmaCyte Biotech appoints Dr. Matthias Löhr to Board to fill vacancy from Yuen's death","bullets":["Dr. Löhr appointed to Board on March 31, 2022; vacancy created by death of Thomas C.K. Yuen.","Compensation: $12,500 cash per quarter, annual grant of 334 restricted shares and a 5-year option for 334 shares (fully vested).","Dr. Löhr is Professor of Gastroenterology & Hepatology at Karolinska Institute; led prior Phase 1/2 and Phase 2 trials of the company's pancreatic cancer treatment.","He will serve on the Compensation and Nominating Committees; independence under Nasdaq rules confirmed.","No family relationships or related party transactions with the company disclosed."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-22-002335","json":"https://secwatch.observer/filing/0001683168-22-002335.json","markdown":"https://secwatch.observer/filing/0001683168-22-002335.md","text":"https://secwatch.observer/filing/0001683168-22-002335.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1157075/000168316822002335/0001683168-22-002335-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1157075/000168316822002335/pharmacyte_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T09:19:19.249090+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3a3e4a13b3","claim":"Thomas C.K. Yuen departed as Director at PharmaCyte Biotech, Inc..","evidence_excerpt":"vacancy created by the recent death of Thomas C.K. Yuen","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1157075/000168316822002335/0001683168-22-002335-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"deceased"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"6ac80c61ee","claim":"Matthias Löhr was appointed as Director at PharmaCyte Biotech, Inc..","evidence_excerpt":"On March 31, 2022, the Board of Directors (\"Board\") of PharmaCyte Biotech, Inc., a Nevada corporation (\"Company\"), appointed Matthias Löhr, MD (\"Dr. Löhr\") to the Board to fill a vacancy","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1157075/000168316822002335/0001683168-22-002335-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}